- NewsCategory：
- All Company news Industry news
common105One result
-
1031
Gotham Therapeutics Establ™φishes Advanced Oncology Profiling Cascad§•₽φe with ProQinase to Progress its Portfolio δ<±of Epitranscriptomic Drug Candidates
Gotham Therapeutics Establis→€hes Advanced Oncology ProfΩ®☆₽iling Cascade with ProQinase to Progπ≈♥≠ress its Portfolio of Epitranscr≥×iptomic Drug CandidatesWEDNESDAY, OCTOBER 3÷→0, 2019Gotham Therapeutics, a biotechnology compa"≥±ny developing a novel drug class targetiδ ∑ng RNA-modifying proteins, and ProQinase, an earl≤↕≥y stage drug-discovery company☆, recently acquired by M£★Ωalvern/PA-based Reaction Bio≠≈logy Corp., today announced that they have establ →♦¥ished an array of advanced biochemical and c€↕ ellular assays to characterize epitransc☆∏riptomic-directed compounds.“Establishing tailo™★∏♦red target engagement,§ ÷≤ cell biology, pheno↔™typic, and in-vivo assays to evaluπλate compounds originating f₹¥¶rom our three most advanced epitranscriptomic>€↔← programs in parallel is a crucial next step toλ♥✔ develop our broad pipel★≈ine towards the clinic,” said Dr. Gerhard Müll"₽er, Chief Scientific Officer of Gotσ÷↓∞ham Therapeutics. “By pursuing the full ra±§¥nge of the reader-writer-eraser contiλγβnuum, we are able to ×÷focus on targets with the most compel♥ •ling links to disease and advance those pro¶¥★grams in tandem.”“Com♣σbining our high proficiency i÷₹n providing customized solutions as early s ≠₩×tage drug-discovery services, in₹∑cluding tailor-made biochσδ←emical and cell-based assays, with Gotham’s Ω∏φexpertise in epitranscriptomics, we w"™ ere able to establish in a v↑♣ery short time a set of customiz∏↔↔∞ed enzymatic and cellular assays∏λ for compounds addressing three different ∏←•mRNA-modifying targets,” said Dr. Sebastian Dαempe, Chief Executive O÷÷•≥fficer of ProQinase. “We ™£look forward to supporti§↑ng Gotham as the company advance≈✔s its programs into lead>± optimization and to continued work with the Goλ≥tham team assisting the compa♦✘ny to advance its broad pipe♦∑line in a time-effective manner.”In♣ addition to establishing a tail≠ or-made profiling cascade fo±↓→✘r compounds from its thr↔♥☆ee most advanced programs,↕♠ Gotham has also made progress in streng •$thening its drug discovery♦§ engine and developing its candidate $ base. Gotham previously comp<←λleted the gene-to-lead pφ§hase for its drug discovery project targeting tΩ≥ he METTL3/METTL14 complex anε★d established a robust discovery process as δ≥a platform for future projects. The compan☆"→y has also generated a library of"δφ high-quality compounds tai≤★↑lor-made for accelerated hit generation and hiβ£∞t-to-lead expansion against large parts of$λ&λ the epitranscriptomic target space. This ↔§library includes a collection of β®✔over 2,000 analogues co₹↑Ωvering over 80 distinct chemotypes that σwill be used to further accelerate Gotham’s§> drug discovery efforts as i₩♦&t expands its pipeline.T™>σαhe original link:https:÷↕σ//www.pharmafocusasia.com/news/gotham-tπ€♦±herapeutics-establishes★✘©-advanced-oncology-profiling-cascad&±e-with-proqinase-to-progres<↕>s-its-portfolio-of-epitranscriptomic-drug-♣$γ"candidates2019 Asia-pacific pharma IP Leade≤÷ €r Summit: http://en.zenseegroup.c♦≥om/p/510934/will be held in Beijing&nbsφ€p; on November 14-15, ™>and will attract more than 500 industry ✔πexperts from domestic and foreign pharmaceutic±&ε✘al companies, biotechn< ₹¥ology companies, governments±✔♣, associations, law f<✘±∏irms, intellectual proper↑↔∏ty agents and other companies to attend.Officia®•♥l registration and consultation ↕λ€channels:Contact：AnnPhone: 021-65650305E✘αmail：Marketing@zenseegroup.comhttp://en.zen×♥®↕seegroup.com/p/510934 -
1030
Gilead and Glympse Bio Announce Stratλ₹× egic Collaboration for Use § ≤of Biomarker Technology in NASH Clinical Develo§ ₹pment
Gilead and Glympse Bio Announce Strategic C©→£αollaboration for Use of↓λ Biomarker Technology in NASH Clinical De≤♥✘velopmentTUESDAY, OCTOBER 29, 2019Gilead S≥$ >ciences Inc. and Glympse ≥α∞Bio, Inc., today annouλ£↓nced that the companies hav ☆♣e entered into a strat ¶egic collaboration in nonalcoholic steaλ₩tohepatitis (NASH) clinical develop→ ment. Glympse Bio’s proprietary synthe≥→tic biomarkers – bioengineered to identify staφ∏ge and progression of dise☆π↑ase as well as early detection of treatmen§÷t response – will be used to determine clin"☆ical trial participants’ stage of disea¶∞Ωse at initial screening and to ♦×determine responses to study treatment in Gileadδ←φ<’s NASH clinical program.“We ar₹€γe excited about the opportunity to p₽≤artner with Glympse Bio to help inform our NAS≈"÷H development program,” said β≥Mani Subramanian, MD, PhD Senior Vice Presiβ↑dent, Liver Diseases, Gilead Sciences. “By utiliz™∑ing this innovative technology, weπ♦π× hope to better charact₹★erize this complex disease and improve ou®≥r understanding of how our compounds impact di↓'✔sease progression.”Glympse Bio’s proprietary♦→↓> technology, Glympse β↓Inside™, combines synthetic biomarkers with™←♥ machine learning approaches to identify tα✘♥he stage and monitor ♣'progression of important, comple≥± x diseases such as cancer, fibro♦★sis, inflammation, and infect→≠ions, in real time.“We are ♣γvery excited about partnering w×←≤ith Gilead, a leader in drug developme™λ¥nt, to help drive earlier and more favorable ou®σ↔♥tcomes for patients,” said Caroline J Loew, Pre ≤sident and CEO, Glympse Bio. “Gilead’s∑λ≈ commitment to developing innovative medici¥nes in areas of high unmet m♠ ↓edical need aligns with our mission of tran≠✘φsforming disease detection and measuring treatme×'nt response, all with thλ≈e goal of helping improve the lives of ∑"♠patients.”information source←':pharma focus AsiaThe original link:https:http<σλs:https://www.pharmafocusasia.com/ne£πws/gilead-and-glympse-bio-announce-strategic-c✘÷ollaboration-for-use-of-biomarker£∞-technology-in-nash-clinical- ±≥development2019 Asia-pacific pharma IP Le↔αader Summit:http://en.zenseegroup.com/p/→≠510934/ will be heα↑ld in Beijing on N<↔≥☆ovember 14-15, and will attract more than 500 ind±★€γustry experts from domestδ∏ic and foreign pharmaceutical companies, biote Ω×chnology companies, governmen→'Ωts, associations, law firms, intellectual pro$ε® perty agents and other companies to attend.Of±€✘λficial registration and consulta↓®tion channels:Contact：AnnPhone: 021-6565030☆≥∞÷5Email：Marketing@zens$σφeegroup.comhttp://en.zens∑≈"eegroup.com/p/510934 -
1029
HistoIndex Announces§ Global Partnerships To Expand AI-Ba£$sed Digital Pathology Platf&πorm
HistoIndex Announces Global Partnerships To≤∞ Expand AI-Based Digital Pathology Platf$₹βormMONDAY, OCTOBER 28, 2019HistoIndex ann¥↓ounces the expansion of its AI-bσσ€£ased digital pathology&↑δ platform towards large-scale ¶NASH preclinical programs for pharmaceutica& l and biotech companies to achie>♠ve quantifiable and reproducibδδ₹le data on therapeutic responses in NASH ↔♠× animal models, and to aid CROs ↕×as well as research agencies in vali¶✘dating new models mimicking the NASH disease$™.Published preclinical stu™¶®dies have demonstrated the σ✔use of HistoIndex's fully quantif→€€iable Second Harmonic Generation (SHG)φ§≥ technology as a highly accurate stain-fr₽→∞ee method that can monitor the efficacy >¶of various therapeutic a←↑gents, by quantifying more than 450 ≥→NASH-associated parametγ→∞ers in fibrosis, inflammation, ballooningφ and steatosis. The information of these NAS☆♥•H-associated parameters gathered from the e≥∑β≥ntire liver tissue, provides comprehensive♥•↔ insights on the mechanism of action of thπ♥λe therapeutic agent. As a drug discovery t₽ >ool, HistoIndex's SHG-'σ↕enabled digital pathology plat≠÷≠ form will allow pharmaceσδ&σutical and biotech companies to sele✔↔÷∞ct promising lead candidates for further optimiz×Ω₽ation and make informed decisions in the mana≈εgement of their NASH dru₹×γ>g development pipeline.In♠≈ addition to ongoing NASH clinical trial∏∑♦s, HistoIndex is currently§σ±€ involved in multiple preclinic♠®&al studies, most of which are cΩ"→onducted by major pharmaceutical and biotβ™₹ech companies, medical universities,≈π CROs and research agencies. Notably, HistoIn♥Ω≤ dex has recently entered into a collaborat↑↑αion with the A*STAR's Genome In±εstitute of Singapore €γ↓(GIS) to validate their in v✘✔ivo and in vitro NASH models bas•ΩΩφed on Asian-centric clinic$→al data. Says Professor Patrick Ta↓'←n, Executive Director of the Genome Institu± ±te of Singapore (GIS), "At GIS, we conduct our ↓♥♣'preclinical studies on fatty liver involving dat€Ωa from animal models based on patieΩ©÷πnt-derived transcript←π₽↑omic data. This has a♠™₩ high translational potential ♣&φ♠as it helps us to pinpoint new th≠" ✘erapeutic targets and their validation. The&γ÷©refore, using a fully quantitative, reliabl∑→λβe and objective pathological evaluation su₽&Ωch as HistoIndex's AI-basσ↔ed digital pathology platform is essen₹φ↕tial to the success of our efforts in ther™♥γapeutic target discovery."HistoIndex is also σ☆₽★a partner with globally-renowned CRO,¶€σ WuXi Apptec, in advancing their NASH pre &≤clinical programs with advanced R→✔•"&D and smart imagin≤¥g analysis capabilities. Published stu<₩±dy data will be available for discussio✔εns during networking←₹ opportunities throughout AASLD's The Liver ≈φ★∞Meeting® in November 20↕ ♣19. "We are very excited toΩ↓☆ extend our AI-based SHG platform to prec★∞♣linical studies to help companies with drug disco♠₩very programs select p£≠♦<romising lead candidates for further optimiza¥"tion and subsequent clinical £♣development," says Dr Poonβπ Thong Yuen, Chief Executive Offi φcer of HistoIndex. "Our SHG ασ$φimage analysis platform has already been u×φ↕sed to analyze the efficacy of a series of↕ promising drug candida♦λtes for NASH within various an÷$♣imal models commonly-used by €≠₩the industry, and we believe these preclini§↓α cal partnerships will he> ∏lp drive the adoptio≥÷♠n of our platform si¥φgnificantly."information so÷σ≤δurce:pharma focus AsiaThe original ∑₽'link:https:https://ww&→w.pharmafocusasia.com/news/histoi♦♥↕♣ndex-announces-global-partnerships-t¥↔λ↔o-expand-ai-based-digital-pathology-platform20 γ§∑19 Asia-pacific pharma IP Leader S•ummit: http://en.zenseegroup.com/p/510934/will₩♥↓↓ be held in Beijing&γ÷φnbsp; on November 14-15,←₹ and will attract more tΩ™™han 500 industry experts'↑₽¥ from domestic and foreign pharmaceutica≠∏γ¥l companies, biotechnology $∏companies, governments, associations, law★∏ firms, intellectual property ag$₩<≠ents and other companies ε₽to attend.Official regi¶"γstration and consultation channels:Contact：AnnPh€ one: 021-65650305Email：Market&✘ing@zenseegroup.comhttp://en.zensee ♥group.com/p/510934 -
1028
AVROBIO Receives Orphan-Drug Designation from thα ±e U.S. FDA for AVR‑RD‑02 for the Treatme♠•≥nt of Gaucher Disease
AVROBIO Receives Orpha€ n-Drug Designation from the U.₹"S. FDA for AVR‑RD‑02 for the Treatmen₽↔t of Gaucher DiseaseFRIDAY, OCTO≥ ΩBER 25, 2019AVROBIO, Inc., today announced that t'×→¥he U.S. Food and Drug Administratio↓γ$n (FDA) has granted orpΩ ± han-drug designation for the →★Company’s investigational gene thera♦£py, AVR-RD-02, for the treatment ∑&of Gaucher disease. AVR-RD-02 consists of t↕♥he patient’s own hematopoietic stem cel©₹ls, genetically modified to express glucocerebΩΩΩrosidase (GCase), the enzyme that is dδ÷®eficient in Gaucher disease. The Com♥↕ pany is actively recruitin♣±☆g in Canada for its Ph•>ase 1/2 clinical trial of AVR-RD-02, which seekΩ↓→s to evaluate the safety↔© and efficacy of the γ¶therapy in patients with Type 1 Gaucher di☆₽sease.“Under the existing s€γ©<tandard of care, patien÷₩βγts with Gaucher disease aε₩re bound to a lifelong infusion schedule of ¥δ♦™enzyme replacement therapies,✘₹☆£ and still experience painful and σ✘progressive symptoms such as debiliφ φtating musculoskeletal pain ÷δπ¶and fatigue,” said Birgitte Volck, MD, PhD☆☆δ, President of Research and Developm¥φαent at AVROBIO. “Orphan-®∏≥drug designation recognizes the unmet need of®δ₹₽ populations with rare diseases like ↔÷∏Gaucher where AVROBIO strives to tran'✔&sform lives by addressing∑ ♣÷ the underlying cause of §α♦ the disease with a single doseβ→ of gene therapy.”Orphan-dru™£&g designation is granted by the •εα FDA to drugs and biologics wεφδφhich are intended for th§&e safe and effective treatmen♠♠ t, diagnosis or prevention of rare diseas↑✔←es or conditions that affect fewer than 20'♣≤0,000 people in the ₩±United States. Orphan-drugΩ₹✔ designation provides certain φ∏incentives, which may include tax cred∞✔±"its towards the cost of c∏§linical trials and prescription drug user fe∞&≈e waivers.information source:pharma f€§÷★ocus AsiaThe original link:https:https↑>"'://www.pharmafocusasia.com/news/avrobio-recei£↔δves-orphan-drug-designat≥©ion-from-the-us-fda-fo∑ πr-avrrd02-for-the-treatment-of-ga€φ✔ucher-disease2019 Asia-<"₹pacific pharma IP Leader Summit: http://'☆φ₹en.zenseegroup.com/p/510934/will be held in ✔Beijing on&nb₩↓ sp;November 14-15, and will attract more ✘than 500 industry experts from domestic → ×βand foreign pharmaceutical γ☆ →companies, biotechnology compa£ →nies, governments, associat♣ <∏ions, law firms, intellectual pr↕♠operty agents and other co✔βλΩmpanies to attend.Official registra•÷β₹tion and consultation channels:Contact：£×↑AnnPhone: 021-65650305Email：Marketin☆♥g@zenseegroup.comhttp://en.zenseegroup≥ ↓.com/p/510934 -
1026
AZTherapies Strengthens Neuroinflammation-Targeλ>✔ted Pipeline Through AcquiδΩ≠sition of Smith Therapeut✘✔" ics
FRIDAY, OCTOBER 25, 2019AZTherapies, λγInc., a biopharmaceutical☆β company developing therape →utics to extend brain health, today announced♠ the acquisition of Smith Therapeutics, a prΩα'ivate biopharmaceutical company with •λa shared goal of targeting neuroinflamm' γation to treat neurodegenerative dise<λ®ase. Smith Therapeutics’ Founder and Chief Execu•∏λtive Officer Philip Ash→♣ ton-Rickardt, Ph.D., has¶ joined the senior leadership team at AZTherapies as Senior Vice Presi♦ ←♣dent of Immunology. Financial termsΩ≈≈ of the acquisition were not disclosed.S∏" &mith Therapeutics’ proprietary research platf<'←orm focuses on the use of modified ™♥↑↓T cells to restore a healthyα↔$ balance of inflammatory and regula®γtory cells in the brain. To date, Smith has ' successfully engineered imm™unosuppressive T regulatory (Treg♠♠ ) cells with Chimeric Antigen Receptors ™★ (CARs) targeting brain glia'↑l cells. Previous research ha<πφs demonstrated the ability of ""©Tregs to dampen microglial a₽♣ctivity and reduce neuroinflammation in model±φφs of neurodegeneration, suggesting α¥their potential utility in the treatm 'ent of diseases includinγ'↓g Progressive Supranuclea ♠ r Palsy (PSP), Alzheimer’s d♣≈✘φisease, Parkinson’s disease, Huntington’s disease<, Amyotrophic Lateral Sclerosis (ALS ® ), and others.“This acqu±δ→isition represents a meaningfu€<→l step forward for us as we continue to strenδ☆®gthen our leadership posi☆∑∑tion in the development of therapies targeti→₩ ng neuroinflammation to stop or slow the pr"✘✔±ogression of neurodeg>♦σenerative diseases,” said David R. ↑←'Elmaleh, Ph.D., Founder, CEO, and Ch¥λ≤≥airman of AZTherapies. “We are↔↓ excited to be working with Philip a¥±π£s we add this cutting-edge techn÷₹±ology to our portfolio oλφf innovative programs. An esteemed immuno↔★logist and inventor of the technology, Philip bri↕ngs unparalleled expertise to the comp≥← any and we look forward to≤♥ advancing this CAR-Treg program further<§ into IND-enabling studiα™es and into clinical development as rap&↕idly as possible.”Dr. Ashton-Rickardt commen•&γted on the acquisiti ©δon and his appointment: “Our sharedδ ♠ε rationale of targeting ne"Ω&uroinflammation as the root cau≥↕se of neurodegenerative λ™<®disease makes this acquisition a grea÷®± t strategic fit for us. With AZThe♣λrapies’ expertise in drug development ≈₹÷☆and clinical trial executi★α©δon, we believe that together, we are well po"★≠"sitioned to advance our CAR-Treg technology a₩♣β₽nd fundamentally change δσ¥♦neurodegenerative disease progress$'₩∑ion.”Prior to launching Smith Therapeutics in 2017, Dr. Ashton-Rickardt was Chair €&Ω in Immunology at Imperi"≤γal College London, Visiting Prof ₩essor, Brigham and Women’s Hospital, Ha' rvard Medical School, and Associate Prof₹∏essor in the Department of Pathology at the Uni§±versity of Chicago. His work has been reco≠™€gnized by his peers through the award of tenu™≥γre from The University of Chica$←©go and by his fellow citizens as a recipie"α®nt of the Early Career Award for Scienti≠↕★≥sts and Engineers fro$m President Bill Clinto₽₽∑n. He has published more than 6∑→©5 peer-reviewed papers in more than 30 academ↕↔☆'ic journals (includinε↓¶g Cell, Science, Immunity, and Na"↓ture Immunology), ha₽∑s served as an editor for several academic jou₽rnals, and has been a member of gran φ ±t review boards globally. Dr. Ashton-Rickardt©<σ received a B.Sc. in Biochemistry from the U<♦×♦niversity of London, King’s College wi↔♣±th honors, a Ph.D. in ←∑♠Molecular Biology from the University of Edinburg> h, and completed post-doctoral work at₩™< the University of Edinburgh and the Massachus±¥etts Institute of Technology in Molecular Bi¥$ ology and Molecular Immunology, respectively.₽₽information source:pharma focus AsiaThe γδoriginal link:https:https://wwπφw.pharmafocusasia.com/news≠Ω /aztherapies-strength ₩★ens-neuroinflammation-targeted-pipeline-through-aε ¶cquisition-of-smith-therapeutics2019 Asia-pac'εific pharma IP Leader S£≥∑±ummit: http://en.zenseegroup.com/✔δ"&p/510934/will be held in&n&πbsp;Beijing on November 14-15,×≈< and will attract more than 500 indu≤±πstry experts from dom✘">estic and foreign pha÷ ♠rmaceutical companies, biotechnology companφ¥∞ies, governments, associationsε≤ε₩, law firms, intellectual prφλ'operty agents and other co&™§mpanies to attend.Official registrationΩ&♣ and consultation channel≥∞s:Contact：AnnPhone: 021-65650305Email：Marketing↓α↔@zenseegroup.comhttp://en.zenseegroup.co÷→↔εm/p/510934
Contact Us
Zensee_Daystar online
© 2011-2016